hemoragic Stroke. Intracerebral haemorrhage in hemisphere, unspecified
Conditions
Interventions
Intervention 1: 20% Vial Human Albumin with total dosage of 1 gram per kilogram Body Weight infusion during 7 days within 2 hours daily. Intervention 2: Plasebo Vial as the Same Dose of Albumin.
Treatment - Drugs
Placebo
20% Vial Human Albumin with total dosage of 1 gram per kilogram Body Weight infusion during 7 days within 2 hours daily
Plasebo Vial as the Same Dose of Albumin
Sponsors
JondiShapur Ahvaz university of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 83 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1.Primary supratentorial ICH; 2.18. Exclusion Criteria: 1.ICH volume 200 mmHg); 7.Current participation in another experimental treatment protocol; 8.Renal impairment with GFR 2.0; 9.History of or known allergy to albumin; 10. History of or known severe allergy to rubber latex; 11.Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6 months. (An episode of congestive heart failure is any heart failure that required a change in medication, diet or hospitalization); 12.Acute myocardial infarction in the last 6 months; 13.Elevated serum troponin level on admission > 0.1 mcg/L; 14.Known valvular heart disease with CHF in the last 6 months; 15.Known (or in the investigator's judgment) existence of severe aortic stenosis or mitral stenosis; 16.Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months; 17.Suspicion of aortic dissection on admission; 18.Acute arrhythmia (including any tachy- or bradycardia) with hemodynamic instability on admission (systolic blood pressure 4 cm above the sternal angle), (2) 3rd heart sound, (3) resting tachycardia (heart rate > 100/min) attributable to congestive heart failure, (4) abnormal hepatojugular reflux, (5) lower extremity pitting edema attributable to congestive heart failure or without apparent cause, (6) bilateral rales, and/or (7) if a chest x-ray is performed, definite evidence of pulmonary edema, bilateral pleural effusion, or pulmonary vascular redistribution; 20.Current acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy; 21.Prosthetic heart valves; 22.Documented left ventricular ejection fraction < 35%.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient Functional Outcome. Timepoint: At admission time, after one week and after 3 months. Method of measurement: NIHSS. | — |
Secondary
| Measure | Time frame |
|---|---|
| Morbidity and Mortality. Timepoint: At the admision, after one week and 3 month. Method of measurement: Registration of mortality.;Drug side effects. Timepoint: At the admision, after one week and 3 months. Method of measurement: Drug side effects chart. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMorteza Oghbaei, MD
JondiShapurAhvaz University of Medical Sciences
Outcome results
None listed